Chemotherapy of small cell lung cancer: State of the art

Current Opinion in Oncology

Volumn 16, Issue 2, 2004, Pages 136-140

  Chrystal, Kathryn ^a   Cheong, Kerry ^a   Harper, Peter ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Dose intensity; Limited stage; Small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; IFOSFAMIDE; IRINOTECAN; PACLITAXEL; PLATINUM; TOPOTECAN; VINCRISTINE;

ANOREXIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOXICITY; DYSPNEA; FATIGUE; HOARSENESS; HUMAN; LONG TERM CARE; LUNG SMALL CELL CANCER; MAINTENANCE THERAPY; NEUTROPENIA; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SMOKING HABIT; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SMALL CELL; CISPLATIN; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 1642488218     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200403000-00009     Document Type: Review

References (31)

1. Page NC, Read WL, Tierney RM: The epidemiology of small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 2002, 21:305a.
2. Sandler AB: Chemotherapy for small cell lung cancer. Semin Oncol 2003, 30:9-25. This is an excellent review of the chemotherapy for SCLC, covering aspects of extensive-stage disease and LD. It incorporates recent data on a background of current standards.
3. Turrisi AT 3rd, Kim K, Blum R, et al.: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999, 340:265-271.
4. Roth BJ, Johnson DH, Einhorn LH, et al.: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992, 10:282-291.
5. Fukuoka M, Furuse K, Saijo N, et al.: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991, 83:855-861.
6. Evans WK, Feld R, Murray N, et al.: Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med 1987, 107:451-458.
7. Sundstrom S, Bremnes RM, Kaasa S, et al.: Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002, 20:4665-4672. This is a large, randomized phase 3 trial evaluating two commonly used regimens. It confirms previous findings for the superiority of platinum-etoposide in LD and included QoL outcomes.
8. Mascaux C, Paesmans M, Berghmans T, et al.: A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000, 30:23-36.
9. Pujol JL, Carestia L, Daures JP: Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent BrJ Cancer 2000, 83:8-15.
10. Skarlos DV, Samantas E, Kosmidis P, et al.: Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994, 5:601-607.
11. Noda K, Nishiwaki Y, Kawahara M, et al.: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002, 346:85-91.
12. Sandler A, Langer C, Bunn P, et al.: Interim safety analysis of irinotecan and cisplatin chemotherapy for previously untreated extensive stage small cell lung cancer [abstract no. 2537]. Proc Am Soc Clin Oncol 2003, 22:631.
13. Sekine I, Nishiwaki Y, Noda K, et al.: Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI). Ann Oncol 2003, 14:709-714.
14. Niell H, Herndon J, Miller A: Randomised phase III intergroup trial (CALGB 9732) of etoposide and cisplatin with or without paclitaxel and G-CSF in patients with extensive stage small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 2002, 21:293a.
15. Mavroudis D, Papadakis E, Veslemes M, et al.: A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 2001, 12:463-470.
16. Reck M, von Pawel J, Macha HN, et al.: Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. J Natl Cancer Inst 2003, 95:1118-1127. This randomized phase 3 trial investigates the addition of a taxane to standard therapy. It did not demonstrate an OS benefit and had significant toxicity.
17. Prendiville J, Lorigan P, Hicks F, et al.: Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vin cristine with thoracic and cranial irradiation. Eur J Cancer 1994, 30A:2085-2090.
18. Thatcher N, Qian W, Girling DJ: Ifosfamide, carboplatin and etoposide with mid-cycle vincristine (ICE-V) versus standard chemotherapy (C) in patients with small cell lung cancer (SCLC) and good performance status (PS): results of an MRC randomized trial (LU21) [abstract no. 2489]. Pro Am Soc Clin Oncol 2003, 22:619.
19. Lorigan P, Woll PJ, O'Brien M, et al.: Randomised phase 3 trial of dose dense ICE chemotherapy versus standard ICE in good prognosis small cell lung cancer (SCLC) [abstract no. 2490]. Pro Am Soc Clin Oncol 2003, 22:619.
20. Ardizzoni A, Tjan-Heijnen VC, Postmus PE, et al.: Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. J Clin Oncol 2002, 20:3947-3955. This phase 3 study investigated increasing dose intensity of cyclophosphamide-doxorubicin-etoposide chemotherapy.
21. Tjan-Heijnen VC, Wagener DJ, Postmus PE: An analysis of chemotherapy dose and dose-intensity in small-cell lung cancer: lessons to be drawn. Ann Oncol 2002, 13:1519-1530. This is a systematic review of the trials investigating dose intensity.
22. Sculier JP, Berghmans T, Castaigne C, et al: Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung Cancer 1998, 19:141-151.
23. Shepherd FA, Giaccone G, Seymour L, et al.: Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002, 20:4434-4439. This is a large, phase 3, randomized trial investigating maintenance therapy with a novel matrix metalloproteinase inhibitor that included QoL analysis.
24. Komaki R: Combined treatment for limited small cell lung cancer. Semin Oncol 2003, 30:56-70. This is a comprehensive overview of combination chemoradiation therapy for LD.
25. Takada M, Fukuoka M, Kawahara M, et al.: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002, 20:3054-3060.
26. Fried D, Morris D, Hensing T, et al.: Timing of thoracic radiation therapy in the combined modality therapy for limited-stage small cell lung cancer: a metaanalysis. Lung Cancer 2003, 41 (suppl 2):S23.
27. Videtic GM, Stitt LW, Dar AR, et al.: Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol 2003, 21:1544-1549.
28. Glisson BS: Recurrent small cell lung cancer: update. Semin Oncol 2003, 30:72-78. This is a good review of current and new therapies for recurrent SCLC.
29. von Pawel J, Schiller JH, Shepherd FA, et al.: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999, 17:658-667.
30. Eckardt J, von Pawel J, Hainsworth J, et al.: Single agent oral topotecan (PO) versus intravenous topotecan (IV) in patients (pts) with chemosensitive small cell lung cancer (SCLC). An international phase III study [abstract no. 2488]. Proc Am Soc Clin Oncol 2003, 22:619.
31. Masters GA, Declerck L, Blanke C, et al.: Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol 2003, 21:1550-1555.